Results 11,461-11,480 of 21,431 for speaker:Alan Kelly
- Public Accounts Committee: 2015 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 22 - Courts Service (13 Jul 2017) Alan Kelly: I am sorry, but what did Mr. Burns say?
- Public Accounts Committee: 2015 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 22 - Courts Service (13 Jul 2017) Alan Kelly: I know what happened. I just wanted to know if there was a payment.
- Public Accounts Committee: 2015 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 22 - Courts Service (13 Jul 2017) Alan Kelly: Okay; there was no charge, which is fair enough. I knew what had happened to the building; I just wanted to know if there was a transaction charge.
- Public Accounts Committee: 2015 Annual Report of the Comptroller and Auditor General and Appropriation Accounts
Vote 22 - Courts Service (13 Jul 2017) Alan Kelly: Let us say 3 p.m..
- Written Answers — Department of Housing, Planning, Community and Local Government: An Bord Pleanála (13 Jul 2017)
Alan Kelly: 30. To ask the Minister for Housing, Planning, Community and Local Government the reason there are so many board vacancies on An Bord Pleanála; and the actions he is taking to implement the appropriate 2016 review of the organisation. [33106/17]
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I will be brief because both of my questions have already been asked. It is not like me to be brief, Chairman.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I thank the witnesses from both bodies for their honesty in answering our questions, as this is obviously a very emotional topic. I will digress here slightly. There are media reports out today about the drug Entresto. The issues around this particular drug have been talked about for some time now. Seeing as they are here with us today, perhaps the witnesses will clarify the situation...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Some €120 million over five years for all nine?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Ultimately, is this a matter for the Department of Health?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: I asked a very specific question. Ultimately, the NCPE has passed these nine drugs. It would cost €120 million over five years, and I thank Mr. Hennessy for clarifying that. The NCPE has gone through its process and the HSE has gone through its process. The matter is now sitting on the Minister's desk. This is not a political attack and I ask that it not be taken that way. I know...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: That is not acceptable. I asked a specific question and I want an answer.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: That is not acceptable.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: As long as the answer is about that drug and Mr. Hennessy does not name it, that is fine.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Mr. Hennessy still has not answered the question.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Mr. Hennessy has not. Is this a cost-effective drug as recommended by the NCPE? If so, in that scenario, is that unique? Why has it not been funded?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Is Mr. Hennessy saying that every drug recommended by NCPE is cost effective?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Professor Barry does not work for the HSE, so maybe he might elaborate on the questions that I asked, because they do not always have to be answered by the HSE.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Fair enough.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: Is this cost effective?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (12 Jul 2017)
Alan Kelly: To tease this out, are the witnesses saying that there would be no cost-saving?